Recombinant Human NR1H3 Protein，His

NR1H3, also known as Liver X Receptor Alpha (LXRα), is a nuclear receptor that plays a crucial role in the regulation of lipid metabolism, cholesterol homeostasis, and inflammatory responses. Research into NR1H3 has gained significant attention due to its potential implications in various metabolic disorders, including obesity, atherosclerosis, and diabetes. LXRα functions primarily by regulating the expression of genes involved in lipogenesis, cholesterol efflux, and inflammation, thus serving as a key player in maintaining cellular and systemic lipid balance. Studies have demonstrated that activation of NR1H3 can lead to increased reverse cholesterol transport, promoting the clearance of excess cholesterol from peripheral tissues to the liver for excretion. This mechanism positions LXRα as a promising therapeutic target for cardiovascular diseases. Moreover, its role in modulating inflammatory pathways highlights its potential in treating metabolic syndrome and associated complications. Advances in recombinant protein technology have enabled the production of functional NR1H3, facilitating in vitro and in vivo studies. Characterizing the structural and functional properties of this receptor not only enhances our understanding of its mechanisms of action but also assists in the development of selective agonists or antagonists, paving the way for novel therapeutic strategies targeting metabolic and inflammatory diseases. Overall, ongoing research on NR1H3 recombinant protein underscores its significance in metabolic regulation and its promise as a target for innovative treatments in metabolic disorders.